FIELD: medicine. SUBSTANCE: the present innovation deals with ways and compositions of directed impact, supply and activation of preparations dependent on blood platelets to overlap circulation. Antibodies-containing preparations binding blood platelets should be directly supplied to hyperplastic cells or tissues, for example, vascular net or solid-body tumors, then the above-mentioned preparation binds and activates blood platelets which, in their turn, bind and activate other blood platelets. Thus, thrombus is formed caused by blood platelets leading to circulation overlapping. EFFECT: higher efficiency of therapeutic preparations to treat tumors. 25 cl, 3 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| CIRCULATION-OVERLAPPING SOLID-PHASE PREPARATION WITH COVERING BEING OUT OF IMMOBILIZED BINDING PREPARATION | 2002 |
|
RU2295329C2 |
| PEPTIDES OF DIRECTED ACTION OF VEGFR-1/NRP-1 | 2008 |
|
RU2488592C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| NOVEL DUAL-TARGETED PROTEINS SPECIFICALLY BINDING TO DLL4 AND VEGF, AND USE THEREOF | 2014 |
|
RU2648154C2 |
| NUCLEIC ACID STRUCTURE FOR EXPRESSION OF ACTIVE SUBSTANCES THAT CAN BE ACTIVATED BY PROTEASES, PREPARING AND USING | 1998 |
|
RU2204414C2 |
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
| ANALYSES AND METHODS WITH APPLICATION OF BIOMARKERS | 2005 |
|
RU2431676C2 |
| RECEPTOR TARGETING CONSTRUCTS AND USES THEREOF | 2015 |
|
RU2682335C2 |
| BISPECIFIC BINDING AGENTS FOR MODULATING BIOLOGICAL ACTIVITY | 2005 |
|
RU2433831C2 |
| NUCLEIC ACID COMPLEXES AS LIGANDS OF VESICAL ENDOTHELIAL GROWTH FACTOR (VEGF) | 1997 |
|
RU2177950C2 |
